KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Consolidated Net Income: 2009-2024

Historic Consolidated Net Income for Teva Pharmaceutical Industries (TEVA) over the last 16 years, with Dec 2024 value amounting to -$2.0 billion.

  • Teva Pharmaceutical Industries' Consolidated Net Income rose 209.92% to $432.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $658.0 million, marking a year-over-year increase of 125.84%. This contributed to the annual value of -$2.0 billion for FY2024, which is 217.67% down from last year.
  • As of FY2024, Teva Pharmaceutical Industries' Consolidated Net Income stood at -$2.0 billion, which was down 217.67% from -$617.0 million recorded in FY2023.
  • Teva Pharmaceutical Industries' Consolidated Net Income's 5-year high stood at $447.0 million during FY2021, with a 5-year trough of -$4.2 billion in FY2020.
  • In the last 3 years, Teva Pharmaceutical Industries' Consolidated Net Income had a median value of -$2.0 billion in 2024 and averaged -$1.7 billion.
  • In the last 5 years, Teva Pharmaceutical Industries' Consolidated Net Income spiked by 110.55% in 2021 and then slumped by 663.76% in 2022.
  • Yearly analysis of 5 years shows Teva Pharmaceutical Industries' Consolidated Net Income stood at -$4.2 billion in 2020, then surged by 110.55% to $447.0 million in 2021, then slumped by 663.76% to -$2.5 billion in 2022, then soared by 75.52% to -$617.0 million in 2023, then plummeted by 217.67% to -$2.0 billion in 2024.